FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

Nephrology Dialysis Transplantation

Volumn 29, Issue 11, 2014, Pages 2075-2084

  Macdougall, Iain C ^a   Bock, Andreas H ^b   Carrera, Fernando ^c   Eckardt, Kai Uwe ^d   Gaillard, Carlo ^e   Van Wyck, David ^f   Roubert, Bernard ^g   Nolen, Jacqueline G ^g   Roger, Simon D ^h  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c Eurodial   (Portugal)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f DaVita HealthCare Partners   (United States)

^g Vifor (International) Inc   (Switzerland)

^h Renal Research   (Australia)

Author keywords

Anaemia; Chronic kidney disease

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; FERRIC ION; IRON; MALTOSE;

AGED; ARTICLE; BACKACHE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; BLOOD; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRIC COMPOUNDS; FERRITINS; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MALTOSE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84916928192     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu201     Document Type: Article

References (28)

1. Kidney Disease Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012;2:292-298
2. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590
3. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084
4. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098
5. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032
6. Palmer SC, Navaneethan SD, Craig JC et al. Meta-analysis: erythropoiesisstimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23-33
7. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798
8. Solomon SD, Uno H, Lewis EF et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-1155
9. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077-1083
10. Freburger JK, Ng LJ, Bradbury BD et al. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012;125:906-914
11. Gill KS, Muntner P, Layafette R et al. Red blood cell transfusion use in patients with chronic kidney disease. Nephrol Dial Transplant 2013;28:1504-1515
12. Minutolo R, Locatelli F, Gallieni M et al. Anaemia management in nondialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant 2013;28:3035-3045
13. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-1343
14. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699
15. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991;57:175-182
16. Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif 2008;26:151-156
17. Svára F, Sulková S, Kvasnicka J et al. Iron supplementation during erythropoietin therapy in patients on hemodialysis. Vnitr Lek 1996;42:849-852
18. Warady BA, Kausz A, Lerner G et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-661
19. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52:897-906
20. Albaramki J, Hodson EM, Craig JC et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012;1:CD007857
21. Macdougall IC, Bock A, Carrera F et al. The FIND-CKD study-a randomized controlled trial of IV iron versus oral iron in non-dialysis chronic kidney disease (CKD) patients: background and rationale. Nephrol Dial Transplant 2014;29:843-850
22. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470
23. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013;61:992-1000
24. Qunibi WY, Martinez C, Smith M et al. A randomised controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011;26:1599-1607
25. Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:c55-c62
26. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-1605
27. Van Wyck DB, Roppolo M, Martinez CO et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846-2856
28. Charytan C, Bernardo MV, Koch TA et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, activecontrolled, multi-center study. Nephrol Dial Transplant 2013;28:953-964 doi: 10.1093/ndt/gfu209